Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication

Código QR

Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication

Nadyr Damasceno,1 Soraya Horowitz,2 Eduardo Damasceno31,2Ophthalmology Department, Hospital Naval Marcilio Dias, Rio de Janeiro, Brazil; 3Department of Ophthalmology, Universidade Federal Fluminense, Niteroi, BrazilAbstract: The authors describe one case of anterior uveitis after treatment of age-re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Damasceno N, Horowitz S, Damasceno E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/28a84ef5adf246ce964150540090ded2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab
por: Antonopoulos C, et al.
Publicado: (2011)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Martin S Spitzer, et al.
Publicado: (2008)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
por: Dervenis N, et al.
Publicado: (2016)

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Tryfon Rotsos, et al.
Publicado: (2010)

Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
por: Otsuji T, et al.
Publicado: (2013)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim LS, et al.
Publicado: (2015)

Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration
por: Nishimura T, et al.
Publicado: (2012)

Emphysema following vitrectomy with fluid–gas exchange: description of a rare complication
por: Damasceno EF, et al.
Publicado: (2014)

The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
por: Gungel H, et al.
Publicado: (2014)

Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size
por: Fujihara M, et al.
Publicado: (2012)

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
por: Basheer K, et al.
Publicado: (2015)

Is monthly retreatment with intravitreal bevacizumab (Avastin&reg;) necessary in neovascular age-related macular degeneration?
por: Nicola G Ghazi, et al.
Publicado: (2010)

Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
por: Singer MA, et al.
Publicado: (2013)

A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction
por: Fischer N, et al.
Publicado: (2013)

Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration
por: Roberto Gallego-Pinazo, et al.
Publicado: (2011)

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration
por: Mamdouh M Kabeel, et al.
Publicado: (2008)

The effect of intravitreal bevacizumab (Avastin&reg;) on ocular pulse amplitude in neovascular age-related macular degeneration
por: Ehud Rechtman, et al.
Publicado: (2011)

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration
por: Williams PD, et al.
Publicado: (2012)

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
por: Pukhraj Rishi, et al.
Publicado: (2011)

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editor
por: Stewart MW
Publicado: (2015)

Visual outcome of ranibizumab therapy for neovascular age related macular degeneration in the black population: a report of five cases
por: Roopa Vemala, et al.
Publicado: (2010)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto A, et al.
Publicado: (2013)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration
por: P William Conrad, et al.
Publicado: (2008)

Age-related macular degeneration
por: Querques G, et al.
Publicado: (2011)

A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis
por: Singh RP, et al.
Publicado: (2015)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum]
por: Nudleman E, et al.
Publicado: (2017)

A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis [Corrigendum]
por: Singh RP, et al.
Publicado: (2017)

Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
por: Luis Arias, et al.
Publicado: (2010)

Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
por: Hahn P
Publicado: (2014)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova NP, et al.
Publicado: (2016)

Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
por: Fujii A, et al.
Publicado: (2014)

Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab
por: Sukhpal Singh Sandhu, et al.
Publicado: (2010)

Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration
por: Chavan R, et al.
Publicado: (2014)

Prevalence and factors associated with scleral hyaline plaque: clinical study of older adults in southeastern Brazil
por: Horowitz S, et al.
Publicado: (2015)

Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life
por: Inoue M, et al.
Publicado: (2014)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike N, et al.
Publicado: (2019)

Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis
por: Sato T, et al.
Publicado: (2014)

Age-related macular degeneration: current treatments
por: Jean Pierre Hubschman, et al.
Publicado: (2009)

Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting
por: Carneiro AM, et al.
Publicado: (2012)